Mobile website
Archive > Volume 23 Issue 5 > 2016,23(5):682-687. DOI:10.3872/j.issn.1007-385X.2016.05.016 Prev Next
Clinical Research
Clinical efficacy of patients with advanced ovarian cancer treated with DC-CIK cytotherapy
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective:To evaluate clinical efficacy and safety of patients with advanced ovarian cancer treated with autogenous DC-CIK cytotherapy.Methods:Peripheral blood mononuclear cells of 28 patients with Ⅳ stage ovarian cancer who hospitalized in the Department of Tumor Biotherapy, the 81th Hospital of PLA during August, 2011 to January, 2016 were collected, from which DC and CIK were obtained with culture in vitro. DC sensitized by lysate of ovarian cancer HO-8910 line cell and CIK were transfused into the patients with ovarian cancer. Before and after the treatment, clinical efficacy and safety of the patients were observed. Results: After 28 patients with advanced ovarian cancer treated by DC-CIK immunotherapy, overall response rate (ORR) and disease control rate (DCR) of the patents were 7.1% (2/28) and 643(18/28) respectively, overall survival (OS) for 12, 36 and 50 months were 75%, 54% and 42% respectively. After treatment of DC-CIK immunotherapy, proportion of CD3+CD8+ in peripheral blood of the patients significantly increased compared to before the treatment (\[23.35±7.52\]% vs \[29.49±8.16\]%; t=-3.340, P<0.01), CD4+/CD8+ ratio obviously decreased (\[1.61±0.84\]% vs \[1.21±0.74\]%; t= 2.785, P<0.05), proportion of CD3+, CD3+CD4+, CD3-CD56+ , CD4+CD25+ cells and levels of CA125, CA199, TSGF did not significantly change (all P>0.05). There not were any obvious adverse reaction in all the patients after the treatment. Conclusion: DC-CIK cytotherapy could be as a safe and feasible theraputic approach which might improve immune status of the patients with advanced ovarian cancer, increase mid long term survival rate of the patients, and any obvious adverse reaction did not found in the patients treated with the immunotherapy.
Keywords:
Project Supported:
Project supported by the Program of Medical Science and Technology Innovation of Nanjing Military Area Command (No.14MS052)
Clc Number:
